GC Biopharma

GC Biopharma Goodwill

The Goodwill of GC Biopharma (006280.KS) as of Nov 4, 2026 is 118.07 B KRW. In the previous year, Goodwill was 125.61 B KRW — a change of -6.01% (lower).

Goodwill

118.07 BKRW

YoY

-6.01%

Last updated:

Goodwill of GC Biopharma is 2025 118.07 B KRW. Goodwill of GC Biopharma was 2024 125.61 B KRW. It decreases by -6.01% lower compared to the previous year.

The GC Biopharma Goodwill history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Goodwill
Date
Goodwill
Jan 1, 2018
10.18 B KRW
Jan 1, 2019
10.07 B KRW
Jan 1, 2020
10.07 B KRW
Jan 1, 2021
142.48 B KRW
Jan 1, 2022
142.48 B KRW
Jan 1, 2023
142.48 B KRW
Jan 1, 2024
125.61 B KRW
Jan 1, 2025
118.07 B KRW
The GC Biopharma Goodwill history
YEARGoodwillYoY
118.07 BKRW-6.01%
125.61 BKRW-11.83%
142.48 BKRW0.00%
142.48 BKRW0.00%
142.48 BKRW+1,315.55%
10.07 BKRW0.00%
10.07 BKRW-1.14%
10.18 BKRW-32.73%
15.13 BKRW-15.20%
17.85 BKRW-2.92%
18.38 BKRW+45.96%
12.59 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GC Biopharma Stock analysis

What does GC Biopharma do? GC Biopharma Corp generates revenue through the production and sale of pharmaceutical products such as blood products, general products, vaccines, over-the-counter drugs, diagnostic reagents, placental injections, cell therapies, and blood diagnostic products. The company also offers genome analysis services. Its primary customers include healthcare providers and institutions requiring pharmaceuticals and diagnostic solutions. The firm targets segments focused on biopharmaceutical manufacturing and genomic healthcare services. Green Cross Corp, the parent company, operates under the same business model, emphasizing pharmaceutical manufacturing and genomic services. The company's product portfolio spans blood-related treatments, vaccines, and advanced diagnostic tools, catering to both general medical needs and specialized healthcare applications. Revenue streams are derived from direct sales of these products and services to healthcare sectors. The business model integrates the production of traditional pharmaceuticals with innovative genomic services, creating a diversified revenue base. Key segments include blood product manufacturing, vaccine development, and diagnostic reagent sales, alongside cell therapy and placental injection offerings. Customers are primarily healthcare institutions and providers seeking comprehensive pharmaceutical and diagnostic solutions. GC Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GC Biopharma stock

Goodwill of GC Biopharma is 118.07 B KRW in 2025.

Goodwill of GC Biopharma changed from 125.61 B KRW to 118.07 B KRW, representing a -6.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Goodwill GC Biopharma since 2006 – with annual values, charts, and detailed analysis.

Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.

Goodwill's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's GC Biopharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — GC Biopharma

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — GC Biopharma